Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China.
The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Medicine (Baltimore). 2022 Dec 30;101(52):e32409. doi: 10.1097/MD.0000000000032409.
The treatment of acupoint catgut embedding (ACE) effective and safe for patients with chronic low back pain (CLBP) is not yet known. This systematic review will objectively and systematically evaluate the efficacy and safety of ACE in CLBP according to the existing evidence.
The protocol of this systematic review and meta-analyses has been registered in PROSPERO with the registration number CRD42019142256. The following electronic databases from inception to November 29, 2022 will be searched: PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI), Wan Fang Data and Chinese Science Journal Database. Randomised controlled clinical(RCTs) using ACE to treat CLBP will be included. Outcomes will include pain intensity, instrument with assessment function and disability, quality-of-life, and costs. Adverse events will be reported for safety assessment. By screening the titles, abstracts, and full texts, two independent reviewers will select studies, extract data, and assess study quality. Data synthesis, sensitivity analysis, subgroup analysis and risk of bias assessment will be conducted using RevmanV.5.3 software. The Grading of Recommendations Assessment, Development and Evaluation system will be used to assess the quality ofthe evidence.
The efficacy and safety of ACE in the treatment of CLBP has not yet been determined.
This systematic review will objectively and systematically evaluate the efficacy and safety of ACE in CLBP according to the existing evidence, which can give high level clinical recommendations to improve patient care and clinical outcomes.
穴位埋线(ACE)治疗慢性腰痛(CLBP)的疗效和安全性尚不清楚。本系统评价将根据现有证据客观、系统地评价 ACE 治疗 CLBP 的疗效和安全性。
本系统评价和荟萃分析的方案已在 PROSPERO 注册,注册号为 CRD42019142256。将从建库至 2022 年 11 月 29 日检索以下电子数据库:PubMed、Cochrane 中央对照试验注册库(CENTRAL)、EMBASE、Web of Science、中国国家知识基础设施(CNKI)、万方数据和中国科学期刊数据库。将纳入使用 ACE 治疗 CLBP 的随机对照临床试验(RCT)。结局指标包括疼痛强度、具有评估功能的工具和残疾、生活质量和成本。将报告安全性评估的不良事件。通过筛选标题、摘要和全文,两名独立评审员将选择研究、提取数据和评估研究质量。使用 RevmanV.5.3 软件进行数据合成、敏感性分析、亚组分析和偏倚风险评估。将使用推荐评估、制定与评估系统(Grading of Recommendations Assessment, Development and Evaluation,GRADE)评估证据质量。
目前还不能确定 ACE 治疗 CLBP 的疗效和安全性。
本系统评价将根据现有证据客观、系统地评价 ACE 治疗 CLBP 的疗效和安全性,为改善患者护理和临床结局提供高级别的临床建议。